CRSP Articles, CRISPR Therapeutics AG - From 01/17/24

On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units....

ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creatin...

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 2.15% on an annualized basis producing an average annual ret...

Cathie Wood-led Ark Invest made a notable move in the market by selling a significant portion of its Coinbase Global Inc (NASDAQ:COIN) shares on Tu...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 years ...

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 3.11% on an annualized basis producing an average annual ret...

Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic ch...

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the...

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory aut...